放疗联合顺铂联合或不联合拉帕替尼治疗非人乳头瘤病毒头颈癌:一项2期随机临床试验
这项多中心2期双盲安慰剂对照随机试验纳入127例III至IV期非HPV头颈癌患者,随机接受放疗联合顺铂联合拉帕替尼或安慰剂。最终分析未提示拉帕替尼组无进展生存期(HR 0.91,95%CI 0.56-1.46,P=0.34)或总生存期(HR 1.06,95%CI 0.61-1.86,P=0.58)改善,3-4级急性及晚期不良事件率无显著差异。
要点
- 在放疗联合顺铂基础上加用拉帕替尼未改善非HPV头颈癌的无进展生存期(HR 0.91,95%CI 0.56-1.46,P=0.34)。
- 总生存期亦无显著获益(HR 1.06,95%CI 0.61-1.86,P=0.58)。
- 两组3-4级急性及晚期不良事件率无显著差异。
核心结论
- 在这项随机临床试验中,拉帕替尼双靶点抑制EGFR-ERBB2似乎未增强放化疗的获益。
- 尽管该试验结果表明招募非HPV头颈癌特异性试验是可行的,但必须研究新策略以改善这一预后不良人群的结局。
研究设计与样本
- 多中心、2期、双盲、安慰剂对照随机临床试验,2012年10月18日至2017年4月18日入组142例患者,中位随访4.1年。
- 纳入III至IV期口咽(p16阴性)、喉及下咽癌患者,Zubrod体能状态0至1,符合预定义血液化学标准;127例患者随机(1:1)至CRT联合拉帕替尼组63例或CRT联合安慰剂组64例。
- 干预为70 Gy(6周)联合2周期顺铂(每3周)联合拉帕替尼1500 mg/天或安慰剂。
- 主要终点为无进展生存期(PFS),需69个事件,采用单侧对数秩检验比较;次要终点包括总生存期(OS)。
主要发现
- 最终分析未提示加用拉帕替尼改善PFS(HR 0.91,95%CI 0.56-1.46,P=0.34)。
- 最终分析未提示加用拉帕替尼改善OS(HR 1.06,95%CI 0.61-1.86,P=0.58)。
- 3-4级急性不良事件率:CRT联合拉帕替尼组83.3%(95%CI 73.9%-92.8%)vs CRT联合安慰剂组79.7%(95%CI 69.4%-89.9%),P=0.64,无显著差异。
- 晚期不良事件率:CRT联合拉帕替尼组44.4%(95%CI 30.2%-57.8%)vs CRT联合安慰剂组40.8%(95%CI 27.1%-54.6%),P=0.84,无显著差异。
关键数值与推荐
- 随机入组127例患者,中位(IQR)年龄58(53-63)岁,98例(77.2%)为男性。
- 主要终点PFS的HR为0.91(95%CI 0.56-1.46,P=0.34)。
- 次要终点OS的HR为1.06(95%CI 0.61-1.86,P=0.58)。
- 3-4级急性不良事件率组间比较P=0.64,晚期不良事件率组间比较P=0.84。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with locally advanced non-human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti-epidermal growth factor receptor (EGFR) antibody improves overall survival (OS) of patients with stage III to IV HNC, and preclinical data suggest that a small-molecule tyrosine kinase inhibitor dual EGFR and ERBB2 (formerly HER2 or HER2/neu) inhibitor may be more effective than anti-EGFR antibody therapy in HNC. OBJECTIVE: To examine whether adding lapatinib, a dual EGFR and HER2 inhibitor, to radiation plus cisplatin for frontline therapy of stage III to IV non-HPV HNC improves progression-free survival (PFS). DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 2, double-blind, placebo-controlled randomized clinical trial enrolled 142 patients with stage III to IV carcinoma of the oropharynx (p16 negative), larynx, and hypopharynx with a Zubrod performance status of 0 to 1 who met predefined blood chemistry criteria from October 18, 2012, to April 18, 2017 (median follow-up, 4.1 years). Data analysis was performed from December 1, 2020, to December 4, 2020. INTERVENTION: Patients were randomized (1:1) to 70 Gy (6 weeks) plus 2 cycles of cisplatin (every 3 weeks) plus either 1500 mg per day of lapatinib (CRT plus lapatinib) or placebo (CRT plus placebo). MAIN OUTCOMES AND MEASURES: The primary end point was PFS, with 69 events required. Progression-free survival rates between arms for all randomized patients were compared by 1-sided log-rank test. Secondary end points included OS. RESULTS: Of the 142 patients enrolled, 127 (median [IQR] age, 58 [53-63] years; 98 [77.2%] male) were randomized; 63 to CRT plus lapatinib and 64 to CRT plus placebo. Final analysis did not suggest improvement in PFS (hazard ratio, 0.91; 95% CI, 0.56-1.46; P = .34) or OS (hazard ratio, 1.06; 95% CI, 0.61-1.86; P = .58) with the addition of lapatinib. There were no significant differences in grade 3 to 4 acute adverse event rates (83.3% [95% CI, 73.9%-92.8%] with CRT plus lapatinib vs 79.7% [95% CI, 69.4%-89.9%] with CRT plus placebo; P = .64) or late adverse event rates (44.4% [95% CI, 30.2%-57.8%] with CRT plus lapatinib vs 40.8% [95% CI, 27.1%-54.6%] with CRT plus placebo; P = .84). CONCLUSION AND RELEVANCE: In this randomized clinical trial, dual EGFR-ERBB2 inhibition with lapatinib did not appear to enhance the benefit of CRT. Although the results of this trial indicate that accrual to a non-HPV HNC-specific trial is feasible, new strategies must be investigated to improve the outcome for this population with a poor prognosis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01711658.
引用
- Wong SJ, Torres-Saavedra PA, Saba NF, et al. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37768670. doi:10.1001/jamaoncol.2023.3809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。